Evidence map›Paper›PMID 42246655›Full record

ArticleJournal of the peripheral nervous system : JPNS2026

A Quantitative Assessment of Upper Limb Motor Function Across Disease Stages in Hereditary Transthyretin Amyloidosis.

Mehrnaz Hamedani, Valeria Prada, Sara Massucco, Edoardo Roveta, Marina Grandis, Chiara Gemelli, Irene Schiavetti, Alessio Signori, Cristina Schenone, Marco Luigetti and 16 more

Abstract read
In one paragraph

Article in Journal of the peripheral nervous system : JPNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Mehrnaz HamedaniDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Valeria PradaItalian Multiple Sclerosis Foundation, AISM, Genova, Italy.ORCID https://orcid.org/0000-0001-5756-0576
Sara MassuccoDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Edoardo RovetaDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Marina GrandisDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Chiara GemelliIRCCS Azienda Ospedaliera Metropolitana (AOM), Neurological Clinic, Genova, Italy.
Irene SchiavettiDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Alessio SignoriDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Cristina SchenoneDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Marco LuigettiFondazione Policlinico A. Gemelli IRCCS, UOC Neurologia, Rome, Italy.
Valeria GuglielminoDipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
Maria Ausilia SciarroneDipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesca VitaliDipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID https://orcid.org/0000-0002-3177-1575
Luca Guglielmo PradottoIvrea Civil Hospital - ASLTO4, Ivrea, Italy.ORCID https://orcid.org/0000-0003-1103-1964
Fiore ManganelliDepartment of Neurosciences, Reproductive and Odontostomatology Sciences, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0000-0002-1442-9604
Stefano TozzaDepartment of Neurosciences, Reproductive and Odontostomatology Sciences, University of Naples "Federico II", Naples, Italy.
Giovanni PalumboDepartment of Neurosciences, Reproductive and Odontostomatology Sciences, University of Naples "Federico II", Naples, Italy.
Anna MazzeoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Luca GentileDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Massimo RussoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Marcella De LucaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Federica D'ArmaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Chiara PisciottaDepartment of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID https://orcid.org/0000-0002-3850-076X
Silvia FenuDepartment of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Davide PareysonDepartment of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID https://orcid.org/0000-0001-6854-765X
Angelo SchenoneDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.ORCID https://orcid.org/0000-0002-2604-7830

Funding

AstraZeneca PharmaceuticalsEuropean Union 101156434Ionis Pharmaceuticals Inc.
6 · The paper itself

Abstract

BACKGROUND AND

aimsHereditary transthyretin amyloidosis (ATTRv) is a multisystemic disease where early neuropathy signs are challenging to detect conventionally. This study aimed to evaluate hand motor performance in ATTRv using the Hand Test System (HTS) across disease stages and examine correlations with standard measures.

methodsA total of 113 individuals were enrolled: 74 patients with ATTRv (divided according to Familial Amyloid Polyneuropathy [FAP] stage into FAP0: pre-symptomatic with confirmed TTR mutations, n = 16; FAP1: mild sensory/motor symptoms, n = 40; FAP2: ambulatory with assistance, n = 18) and 39 healthy controls. All participants underwent HTS evaluation; 9-Hole Peg Test (9HPT); handgrip and tripod pinch strength testing; Thumb Opposition Test (TOT); Neuropathy Impairment Score (NIS); Disabilities of the Arm, Shoulder and Hand questionnaire (DASH); and Quality of Life Diabetic Neuropathy (Norfolk QoL-DN) questionnaire. Group differences were analyzed with analysis of covariance and correlations with Pearson's coefficients.

resultsHTS parameters (Touch Duration, Inter-Tapping Interval, Movement Rate) significantly differed across stages between the FAP2 and all other groups, with some parameters distinguishing the FAP1 from the control and FAP0 groups. 9HPT impairment was observed only in the FAP2 group. Grip strength showed subtle changes, especially in the right hands of the FAP1 group, while tripod pinch strength declined during advanced stages. Several HTS parameters were correlated with NIS, DASH, Norfolk QoL-DN, and hand strength. Subclinical carpal tunnel syndrome possibly influenced early-stage results.

interpretationHTS detected stage-related motor differences in ATTRv and correlated them with standard measures, offering increased sensitivity to early neuropathic changes.

Indexed as

Amyloid Neuropathies, FamilialUpper ExtremityAdultAgedDisease ProgressionFemaleHand StrengthHumansMaleMiddle AgedSeverity of Illness Indexamyloidosisearly detectionmotor performanceneuropathysensitivitysensorupper limb

Identifiers

PMID42246655
PMCPMC13238811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.